Regenerative Approach for Angina Pectoris
- Written by
- StemCell Longevita Editorial Team
- Medically reviewed by
- Prof. Dr. Erdal Karaöz TeamProfessor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
- Last reviewed
- Next scheduled review
How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards
A regenerative approach studied for its effect on coronary blood flow, chest pain and heart function for patients with angina.
Can stem cell therapy help refractory angina?
Mesenchymal stem cell therapy is not an approved treatment for angina, including refractory angina despite full medical therapy. Trials of cell-based therapies in refractory angina have reported acceptable safety and some improvement in exercise tolerance in selected studies, but effect sizes are variable and not consistently replicated. Optimised anti-anginal medication, revascularisation where feasible, and cardiac rehabilitation remain the evidence-based path.
Key facts
- Approval status
- Not approved for angina
- Evidence
- Some exercise-tolerance signals; not consistently replicated
- Standard care
- Optimised medical therapy, revascularisation, cardiac rehab
What we know
- Optimised medical therapy and revascularisation strategies have strong evidence for symptomatic angina.
What remains uncertain
- Whether MSC administration reproducibly reduces angina episode frequency in genuinely refractory patients.
Medically reviewed questions
This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.
Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy
Evidence at a glance — Refractory angina
A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.
- Human studies available?
- Yes — including controlled studies
- Randomised trials?
- Randomised trials of cell therapy in refractory angina, with mixed results
- Main outcomes studied
- Angina episodes
- Exercise tolerance
- Nitrate use
- Safety
- Long-term evidence
- Limited
- Regulatory approval for this indication
- United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
- European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
- United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
- Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
- Role at our centre
- Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it
What kind of evidence exists
- Mechanism (laboratory): Documented
- Animal / preclinical: Documented
- Early human (phase 1/2, uncontrolled): Documented
- Controlled human (randomised or sham-controlled): Documented
- Regulatory approval: Not established
Sources
- Systematic reviews and meta-analyses — Refractory angina — PubMed
- Randomised controlled trials — Refractory angina — PubMed
- Registered MSC trials — Refractory angina — ClinicalTrials.gov
- FDA — Consumer alert on regenerative medicine therapies — U.S. Food and Drug Administration, 2024
- Advanced therapy medicinal products: overview — European Medicines Agency, 2025
- ISSCR Guidelines for Stem Cell Research and Clinical Translation — International Society for Stem Cell Research, 2021
- ISSCR Patient Handbook on Stem Cell Therapies — International Society for Stem Cell Research, 2020
Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.
This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.
What is Angina and How Can Stem Cells Help?
Angina pectoris is chest pain or discomfort caused by reduced blood flow to the heart muscle, typically due to coronary artery disease. This occurs when the arteries supplying blood to the heart become narrowed or blocked by plaque buildup.
Traditional treatments include medications and surgical procedures like stenting or bypass surgery. However, many patients continue to experience symptoms despite these interventions, leading to reduced quality of life.
How Regenerative Approach Works
Regenerative medicine approach offers a novel approach by targeting the underlying causes of angina. Mesenchymal stem cells (MSCs) derived from umbilical cord tissue can:
- Angiogenesis: Stimulate the growth of new blood vessels to bypass blocked arteries
- Anti-inflammatory Effects: Reduce inflammation in coronary arteries that contributes to plaque formation
- Tissue Repair: Promote repair of damaged heart tissue and improve cardiac function
- Paracrine Signaling: Release beneficial growth factors that protect and regenerate heart cells
Benefits of Regenerative Approach for Angina
Discover how regenerative medicine can help restore cardiac function and improve your quality of life.
Improved Blood Flow
Stem cells promote angiogenesis, creating new blood vessels to improve oxygen delivery to the heart.
Reduced Inflammation
MSCs have powerful anti-inflammatory properties that help reduce arterial inflammation and plaque progression.
Enhanced Cardiac Function
Treatment can improve heart muscle function and increase exercise tolerance.
Pain Relief
Many patients experience significant reduction in angina episodes and chest discomfort.
Umbilical Cord MSCs
We use highly potent stem cells from umbilical cord tissue for maximum regenerative potential.
Long-Term Benefits
Effects can be long-lasting as new blood vessels mature and cardiac function stabilizes.
How Stem Cells Work for Angina
Regenerative medicine approach for angina pectoris addresses the underlying coronary vascular insufficiency that causes chest pain. Mesenchymal stem cells (MSCs) promote the formation of new blood vessels, repair damaged heart muscle, and improve myocardial perfusion to reduce anginal episodes and improve cardiac function.
MSCs secrete potent angiogenic factors including VEGF, FGF-2, and angiopoietin-1 that clinical studies suggest stimulate the growth of new coronary collateral vessels. This neovascularization bypasses blocked arteries and restores blood flow to ischemic heart tissue.
Stem cells release cardioprotective cytokines that reduce cardiomyocyte apoptosis in oxygen-deprived myocardial regions. Research indicates this cellular rescue mechanism helps preserve viable heart muscle that would otherwise be lost to chronic ischemia.
MSCs modulate the inflammatory environment within atherosclerotic coronary vessels by reducing endothelial inflammation and stabilizing vulnerable plaques. Clinical observations suggest this anti-inflammatory action decreases the risk of acute coronary events.
Stem cells have been reported to affect endothelial repair and nitric-oxide-mediated vasodilation, largely in preclinical models. This improved endothelial function enhances coronary blood flow regulation and reduces vasospasm-related angina episodes.
Who Is a Good Candidate?
Regenerative medicine approach for angina is designed for patients with chronic coronary artery disease who continue to experience symptoms despite optimal medical management.
Ideal Candidates
- Patients with stable angina (CCS Class II-III) who experience chest pain despite maximum tolerated anti-anginal medications
- Individuals with refractory angina who are not suitable candidates for coronary bypass surgery or percutaneous intervention
- Patients with diffuse coronary artery disease affecting small vessels not amenable to stenting or surgical revascularization
- Those who have undergone previous bypass surgery or stenting but continue to experience recurrent anginal symptoms
- Patients with documented myocardial ischemia on stress testing who seek to improve their exercise capacity and quality of life
May Not Be Suitable
- Patients with unstable angina or acute coronary syndrome requiring immediate cardiac intervention
- Individuals with severe decompensated heart failure (NYHA Class IV) or cardiogenic shock
- Patients with severe uncontrolled cardiac arrhythmias or recent myocardial infarction (within 3 months)
- Those with active endocarditis, myocarditis, or other acute cardiac inflammatory conditions
What Results Can You Expect?
Cardiac improvement from regenerative medicine approach follows a gradual timeline as new blood vessels form and heart tissue repairs. Results depend on the severity of coronary disease and overall cardiac reserve.
Initial Recovery
Rest and cardiac monitoring period. Stem cells begin engrafting in ischemic myocardial tissue and initiating angiogenic signaling. Patients should follow activity restrictions as advised.
Early Improvements
Clinical studies suggest early reduction in angina episode frequency and severity. Exercise tolerance may begin improving as new collateral vessels start forming in ischemic territories.
Progressive Results
Significant improvement in exercise capacity and reduction in nitroglycerin use is commonly reported. Stress testing may show improved myocardial perfusion in previously ischemic regions.
Optimal Results
Many patients achieve meaningful reduction in CCS angina classification. Cardiac imaging may demonstrate improved wall motion and enhanced myocardial perfusion at rest and during stress.
Long-Term Benefits
Sustained improvement in angina symptoms and exercise capacity with mature collateral vessel networks. Many patients report significantly improved quality of life and reduced medication burden.
Individual results vary. These timelines are based on clinical observations and are not guaranteed outcomes. Your specialist will provide personalized expectations during your consultation.
Patient Experiences
Real outcomes from patients who chose regenerative medicine at StemCell Longevita Istanbul
"My cardiologist said my heart function improvement was beyond what medication alone could achieve. I'm gardening again for the first time in three years."
"The rehabilitation combined with regenerative medicine accelerated my improvement beyond what anyone expected. Istanbul changed my trajectory."
Care Process
Our comprehensive approach ensures safe and effective treatment with personalized care at every step.
Medical Evaluation
Comprehensive cardiac assessment including ECG, echocardiogram, and blood tests.
Specialist Consultation
Our cardiologist reviews your case and develops a personalized care plan.
Cell Preparation
High-quality MSCs are prepared in our GMP-certified laboratory.
Treatment Administration
Stem cells are administered via IV infusion in our comfortable clinical setting.
Follow-Up Care
Regular monitoring and follow-up appointments to track your progress.
Frequently Asked Questions
Get answers to common questions about regenerative medicine approach for angina.
Watch Our Patient Stories & Expert Insights
See real results and hear from our medical team about stem cell therapy treatments, procedures, and patient outcomes.
All Regenerative Medicine Applications
Explore our comprehensive range of regenerative medicine applications for various conditions. Click any option to learn more.
Related Treatments
Related Articles
Explore our in-depth research articles and guides on related treatments and therapies.
Heart Disease: Stem Cell Approaches to Cardiac Regeneration
Understanding how regenerative medicine approaches may support heart health by promoting tissue repair and supporting cardiac function in patients with various cardiovascular conditions.
Read ArticleStroke Progress: How Stem Cells Support Neurological Wellness
Exploring the potential of regenerative medicine in stroke rehabilitation, including mechanisms of action and reported improvements in motor and cognitive function.
Read ArticleUnderstanding Regenerative Medicine: A Complete Guide
A comprehensive overview of stem cell therapy, including types of stem cells, care processes, safety considerations, and what patients can expect during their wellness journey.
Read ArticleHow Much Does This Cost Worldwide?
Compare this regenerative medicine costs at StemCell Longevita versus clinics in other countries.
| Country | Typical Cost |
|---|---|
| United States | $20,000 – $40,000 |
| United Kingdom | £15,000 – £30,000 |
| Germany | €18,000 – €35,000 |
| South Korea | $15,000 – $28,000 |
| StemCell Longevita (Turkey) | From £7,600 |
Prices based on market research of comparable stem cell clinics offering umbilical cord-derived MSC treatments (2025-2026). Actual prices vary by clinic, cell count, and condition.
Related clinical questions
Where this page sits in the wider picture.